Lung Cancer Symptom Assessment and Management Intervention
This trial is active, not recruiting.
|Sponsor||Dana-Farber Cancer Institute|
|Collaborator||Boston Medical Center|
|Start date||May 2008|
|End date||August 2012|
|Trial size||179 participants|
|Trial identifier||NCT00852462, 07-404, 5R01CA125256|
The purpose of this study is to develop and test the usability of a computerized symptom assessment and management intervention system in a laboratory setting (phase I) and its feasibility in a clinical setting in a group randomized trial (phase II).
|Endpoint classification||safety study|
|Intervention model||parallel assignment|
|Primary purpose||supportive care|
% completion of intervention use and adherence to suggested symptom management strategies.
time frame: 2 years
Health-related quality of life
time frame: 6 months
Male or female participants at least 21 years old.
- HCPs: attending physician, thoracic medical oncologist, expected to work in the setting for at least 2 years.
- Patients: 21 years of age or older; diagnosis of Stage IIIA, IIIB, IV non-small cell lung cancer OR limited or extensive stage small cell lung cancer; receiving care in the out-patient setting; receiving treatment with chemotherapy +/- additional therapies; English speaking.
- Patients: Any patient who needs emergent care, routine visits scheduled less than once a month
|Official title||Lung Cancer Symptom Assessment and Management Intervention|
|Principal investigator||Mary E. Cooley, PhD|
Call for more information